Skip to main
  1. Stocks
  2. GH Research PLC
  3. Forecast
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is viewed positively because its lead program GH001 has already shown unusually strong Phase IIb efficacy in TRD, including a -15.5 point placebo-adjusted MADRS reduction at Day 8, 57.5% remission at Day 8 versus 0% on placebo, and 73% remission at 6 months. The company also has multiple de-risking catalysts, as July 2026 FDA feedback indicated its CMC and proprietary aerosol device plans appear Phase III ready, while its patent was upheld in Europe and U.S. proceedings remain ongoing. With Phase III site selection completed, pivotal doses chosen, and a pathway that may avoid repeated visits and a licensed psychotherapist, the execution profile and commercialization potential look compelling despite regulatory risks.

Bears say

GH Research is facing a highly uncertain investment case because GH001 remains under a clinical hold, and the FDA may refuse to lift it, require additional information, or object to the Phase III design, including the Day 8 endpoint and IDR replication. Even if development proceeds, the company still faces the risk that efficacy seen in earlier studies will not be reproduced in the registrational Phase III trial, while safety, tolerability, or inhalation-device manufacturing issues could halt the program. Commercially, it may struggle with DEA rescheduling, slower real-world adoption, and financing needs for Phase III and any eventual launch, all of which are especially concerning for a single-segment R&D company.

GHRS has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

GHRS Analyst Forecast & Price Prediction

Get the latest GHRS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GHRS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


GHRS Analyst Forecast & Price Prediction

Get the latest GHRS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GHRS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GHRS stock data and trends